Zoetis shares drop 71% since 2021 but remain a buy with strong margins and pipeline potential.

Zoetis Inc., the largest animal-health company, has seen its stock price fall 71% from its 2021 peak, now trading at levels last seen in 2017. This decline is due to reduced pricing power and lower pet medicine volumes. Despite these challenges, Zoetis maintains industry-leading profit margins and is better positioned than competitors to handle price wars because of its diverse product mix and scale. Key risks include patent expirations for major drugs Apoquel and Simparica in 2030 and 2032, but a strong pipeline of 12 new candidates could offset potential revenue losses if at least half succeed. The stock is valued at $113 per share and rated a Buy, as current prices reflect an overly pessimistic scenario where all risks occur simultaneously.

As of Sep 30, 2026 17:41 WIB, Zoetis Inc (ZTS) trades at USD 70.59 on Pluang, showing a modest 0.42% gain for the day. The stock's market capitalization stands at $29.05 billion, with investors holding positions for an average of 69 days. Notably, Pluang users currently show 100% buy interest in ZTS, highlighting strong demand despite the stock's historical price challenges.